CKD-501 0.5mg

DRUG6 trials

Sponsors

Chong Kun Dang Pharmaceutical

Conditions

Diabetes Mellitus, Type 2Type 2 Diabetes MellitusType2 Diabetes

Phase 2

Evaluate the Glycemic Control of CKD-501 in Type 2 Diabetes Mellitus

CompletedNCT01030679

Chong Kun Dang PharmaceuticalDiabetes Mellitus, Type 2

Start: 2007-07-31End: 2008-10-31Updated: 2009-12-16

Phase 3

An Evaluation of Glycemic Control Effects of Mono Therapy CKD-501 in Patients With Type 2 Diabetes Mellitus

CompletedNCT01001611

Chong Kun Dang PharmaceuticalDiabetes Mellitus, Type 2

Start: 2009-10-31End: 2012-01-31Updated: 2013-07-19

Efficacy and Safety of CKD-501 Versus Pioglitazone When Added to Metformin

CompletedNCT01106131

Chong Kun Dang PharmaceuticalType 2 Diabetes Mellitus

Start: 2010-05-31End: 2012-11-30Updated: 2013-02-15

Efficacy and Safety of CKD-501 Added to D150 Plus D745 25mg Therapy in Patients With Type 2 Diabetes

Chong Kun Dang PharmaceuticalType2 Diabetes

Start: 2018-04-26End: 2023-02-10Target: 240Updated: 2018-08-13

The Efficacy and Safety of CKD-501 Added to D150 Plus D759 Therapy in Patients With Type 2 Diabetes

Chong Kun Dang PharmaceuticalType2 Diabetes

Start: 2018-05-02End: 2022-11-30Target: 240Updated: 2018-08-22

Efficacy and Safety of CKD-501 Added to D150 Plus D745 10mg Therapy in Patients With Type 2 Diabetes

CompletedNCT03739125

Chong Kun Dang PharmaceuticalType2 Diabetes

Start: 2017-11-07End: 2020-12-02Updated: 2021-08-25

Related Papers

Comparative Efficacy of Lobeglitazone Versus Pioglitazone on Albuminuria in Patients with Type 2 Diabetes Mellitus.

2020-10-247 citations

Efficacy and Safety of Lobeglitazone Monotherapy in Patients with Type 2 Diabetes Mellitus over 24-Weeks: A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo Controlled Trial

PLoS ONE2014-04-1579 citations

How many unpublished studies? ClinicalTrials.gov (n = 2614 studies): diabetes | Closed Studies | Interventional Studies | Phase 3, 4 | Search Date: Oct 27, 2014

Figshare2014-01-01